All articles by Isaac Hanson

Isaac Hanson

Signal: Eli Lilly’s $176.5m Teva patent infringement loss overturned in US

A District Judge overturned last year’s jury verdict, declaring the application of Teva’s patents overly broad.

Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab

The biopharma giant’s decision to end its partnership with I-Mab follows it ending a trial for the drug early.

Signal: CMR Surgical Raises $165m to continue development of surgical robot

The UK-based surgical robotics company has now raised over $1bn in funding, cementing its unicorn status.

Signal: UK NHS pay row intensifies as doctors launch joint strike

UK public sector doctor’s pay is below that in Germany or the US, and ongoing strike action may lead to more emigration.

Signal: Illumina leads $15m investment in Broken String Biosciences

Embattled biotech giant Illumina has led series A funding into genomics mapping company Broken String Biosciences.

Corporate sustainability needs ESG standards and tools

Global industry leaders are embracing ESG issues but diverging reporting standards pose a challenge to corporate sustainability.

Signal: Roche to refile subcutaneous Tecentriq with FDA after UK approval

Roche planned to launch the new formulation this year, but it will be pushed back after tweaks requested by FDA.

Signal: Kroger to pay up to $1.4bn to settle opioid crisis lawsuits

Kroger’s settlement, alongside the review of the Purdue Pharma bankruptcy case, is proof that the opioid reckoning isn’t over yet.

What does CSRD mean for the pharmaceutical industry? ENGIE Impact explains

Mark Chadwick explains how the EU’s new ESG reporting regulation will impact pharmaceutical companies.

Signal: Pharma giant Novartis to spin-off generics brand

Sandoz, the generics division of Novartis, has underperformed in recent years, but the spin-off may not settle investors.